Amir London - KAMADA Chief Executive Officer

<div class='circular--portrait' style='background:#008000;color: #f8f8f8;font-size:3em;padding-top: 38px;;'>KMD</div>
KMDA -- Israel Stock  

ILA 2,722  148.00  5.16%

Mr. Amir London is Chief Executive Officer of the company. Since July 2015. Prior to that, he has served as our Senior Vice President, Business Development. Mr. London brings with him over 20 years of senior management and international business development experience. Prior to joining Kamada, Mr. London was the COO of Fidelis Diagnostics, a USbased provider of innovative inoffice medical diagnostic services. Earlier in his career Mr. London was the CEO of Promedico, a leading Israelibased 350 million healthcare distribution company, and the General Manager of Cure Medical, providing contract manufacturing services for clinical studies, as well as homecare solutions. Before that, for 10 years, Mr. London was a Partner with Tefen, an international publiclytraded operations management consulting firm, responsible for the firm global biopharma practice. Mr. London holds a B.Sc. in Industrial and Management Engineering from the Technion in Haifa, Israel.
Age: 46  CEO Since 2015      
(972) 8 9406472

KAMADA Management Efficiency

KAMADA has return on total asset (ROA) of 0.0015 % which means that it generated profit of $0.0015 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of 0.0019 % meaning that it generated $0.0019 on every $100 dollars invested by stockholders. KAMADA management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. The current year Return on Investment is expected to grow to 19.30. The current year Return on Average Assets is expected to grow to 15.39The current year Return on Average Assets is expected to grow to 15.39, whereas Total Assets are expected to decline to about 107 M. The current year Total Liabilities is expected to grow to about 44.1 M, whereas Current Liabilities is expected to decline to about 27 M.
The company has accumulated 5.19 M in total debt with debt to equity ratio (D/E) of 4.6 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. KAMADA has Current Ratio of 6.02 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Company Summary

Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. The company was founded in 1990 and is headquartered in Rehovot, Israel. KAMADA operates under Drug ManufacturersSpecialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 429 people.KAMADA (KMDA) is traded on Tel Aviv Stock Exchange in Israel and employs 429 people.

KAMADA Leadership Team

Pnina Strauss, Vice President - Inhalation programs & IP
Itzhak Krinsky, Director
Barak Bashari, Vice President - Operations
Eran Schenker, Vice President - Medical Director
Tuvia Shoham, Independent Director
Michal Stein, Vice President and Medical Director for Immunology
Shani Dotan, Vice President of Human Resources
Liliana Bar, VP of RandD
Yael Brenner, Vice President - Quality
Abraham Havron, Independent Director
Asaf Frumerman, Director
Ruth Wolfson, Senior Vice President - Scientific Affairs
Shmuel Rubinstein, Director
Naveh Tov, Vice President-Clinical Development and Medical Director for Pulmonary Diseases
Michael Berelowitz, Director
David Tsur, Co-Founder and Deputy Executive Chairman
Orit Pinchuk, Vice President - Regulatory Affairs and Quality R&D
Leon Recanati, Chairman of the Board
Gil Efron, CFO, Principal Accounting Officer and Deputy CEO
Jonathan Hahn, Director
Eran Schenkar, Vice President - Medical Director
Gwen Melincoff, Director
Chaime Orlev, Chief Financial Officer
Michal Ayalon, Vice President - Research & Development
Amir London, Chief Executive Officer
Estery GilozRan, Independent Director
Reuven Behar, Director
Eitan Kyiet, Vice President - Business Development
Ziv Kop, Director

Stock Performance Indicators

Did you try this?

Run Balance Of Power Now


Balance Of Power

Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Stocks Correlation. Please also try Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page